What the comprehensive economics of blindness and visual impairment can help us understand

被引:15
作者
Frick, Kevin D. [1 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA
关键词
Economics; blindness; visual impairment; market; government; cost; COST-EFFECTIVENESS ANALYSIS; MACULAR DEGENERATION; RANIBIZUMAB; CATARACT; SURGERY; IMPACT;
D O I
10.4103/0301-4738.100535
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Since the year 2000, the amount written about the economics of blindness and visual impairment has increased substantially. In some cases, the studies listed under this heading are calculations of the costs related to vision impairment and blindness at a national or global level; in other cases the studies examine the cost-effectiveness of strategies to prevent or modify visual impairment or blindness that are intended to be applied as a guide to treatment recommendations and coverage decisions. In each case the references are just examples of many that could be cited. These important studies have helped advocates, policy makers, practitioners, educators, and others interested in eye and vision health to understand the magnitude of the impact that visual impairment and blindness have on the world, regions, nations, and individuals and the tradeoffs that need to be made to limit the impact. However, these studies only begin to tap into the insights that economic logic might offer to those interested in this field. This paper presents multiple case studies that demonstrate that the economics of blindness and visual impairment encompasses much more than simply measures of the burden of the condition. Case studies demonstrating the usefulness of economic insight include analysis of the prevention of conditions that lead to impairment, decisions about refractive error and presbyopia, decisions about disease and injury treatment, decisions about behavior among those with uncorrectable impairment, and decisions about how to regulate the market all have important economic inputs.
引用
收藏
页码:406 / 410
页数:5
相关论文
共 21 条
[1]  
Arrow KJ, 2004, B WORLD HEALTH ORGAN, V82, P141
[2]  
Baltussen R, 2004, B WORLD HEALTH ORGAN, V82, P338
[3]   Eye and visual function in traumatic brain injury [J].
Cockerham, Glenn C. ;
Goodrich, Gregory L. ;
Weichel, L. T. C. Eric D. ;
Orcutt, James C. ;
Rizzo, Joseph F. ;
Bower, C. O. L. Kraig S. ;
Schuchard, Ronald A. .
JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT, 2009, 46 (06) :811-818
[4]   The cost of vision loss in Canada. 2. Results [J].
Cruess, Alan F. ;
Gordon, Keith D. ;
Bellan, Lorne ;
Mitchell, Scott ;
Pezzullo, M. Lynne .
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2011, 46 (04) :315-318
[5]   The magnitude and cost of global blindness: An increasing problem that can be alleviated [J].
Frick, KD ;
Foster, A .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 135 (04) :471-476
[6]   Economic impact of visual impairment and blindness in the United States [J].
Frick, Kevin D. ;
Gower, Emily W. ;
Kempen, John H. ;
Wolff, Jennifer L. .
ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (04) :544-550
[7]  
Jongsareejit Amporn, 2012, Journal of the Medical Association of Thailand, V95, P212
[8]   Why some market reforms lack legitimacy in health care [J].
Laugesen, M .
JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2005, 30 (06) :1065-1100
[9]   Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration [J].
Martin, Daniel F. ;
Maguire, Maureen G. ;
Fine, Stuart L. ;
Ying, Gui-shuang ;
Jaffe, Glenn J. ;
Grunwald, Juan E. ;
Toth, Cynthia ;
Redford, Maryann ;
Ferris, Frederick L., III .
OPHTHALMOLOGY, 2012, 119 (07) :1388-1398
[10]   Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial [J].
Mitchell, Paul ;
Annemans, Lieven ;
Gallagher, Meghan ;
Hasan, Rafiq ;
Thomas, Simu ;
Gairy, Kerry ;
Knudsen, Martin ;
Onwordi, Henrietta .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2012, 96 (05) :688-693